Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.06B in total; no superinvestor holds it.

13F holders, Q3 2025

Institutional positions in Enliven Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
134
+9 vs. Q2 2025
Shares held
59.4M
−34.8K (−0.1%) vs. Q2 2025
Total value
$1.22B
+$23.4M (+2.0%) vs. Q2 2025
New holders
20
59 more added
Sold out
11
32 more reduced

Compare with Q2 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting ELVN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2025: 134 institutions
Q1 2021: 40 institutionsQ2 2021: 31 institutionsQ3 2021: 38 institutionsQ4 2021: 35 institutionsQ1 2022: 31 institutionsQ2 2022: 26 institutionsQ3 2022: 31 institutionsQ4 2022: 36 institutionsQ1 2023: 45 institutionsQ2 2023: 63 institutionsQ3 2023: 61 institutionsQ4 2023: 62 institutionsQ1 2024: 74 institutionsQ2 2024: 93 institutionsQ3 2024: 102 institutionsQ4 2024: 114 institutionsQ1 2025: 122 institutionsQ2 2025: 125 institutionsQ3 2025: 134 institutionsQ4 2025: 126 institutionsQ1 2026: 171 institutionsQ2 2026: 214 institutions
Value heldQ3 2025: $1.22B
Q1 2021: $92.9MQ2 2021: $86.3MQ3 2021: $62.5MQ4 2021: $33.6MQ1 2022: $26.2MQ2 2022: $13.1MQ3 2022: $18.8MQ4 2022: $74.7MQ1 2023: $735.0MQ2 2023: $797.9MQ3 2023: $533.8MQ4 2023: $539.8MQ1 2024: $780.8MQ2 2024: $1.13BQ3 2024: $1.22BQ4 2024: $1.12BQ1 2025: $983.9MQ2 2025: $1.19BQ3 2025: $1.22BQ4 2025: $960.9MQ1 2026: $2.43BQ2 2026: $4.06B
Institutions holding ELVN and their total value by quarter
QuarterHoldersValue
Q2 2026214$4.06B
Q1 2026171$2.43B
Q4 2025126$960.9M
Q3 2025134$1.22B
Q2 2025125$1.19B
Q1 2025122$983.9M
Q4 2024114$1.12B
Q3 2024102$1.22B
Q2 202493$1.13B
Q1 202474$780.8M
Q4 202362$539.8M
Q3 202361$533.8M
Q2 202363$797.9M
Q1 202345$735.0M
Q4 202236$74.7M
Q3 202231$18.8M
Q2 202226$13.1M
Q1 202231$26.2M
Q4 202135$33.6M
Q3 202138$62.5M
Q2 202131$86.3M
Q1 202140$92.9M

Institutions, Q3 2025

Shares, value and share of portfolio for each institution holding Enliven Therapeutics, Inc.; share changes are against Q2 2025.

Institutions holding ELVN in Q3 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Morgan Stanley258,384$5.29M0.00%+3,536+1.4%Added
HighVista Strategies LLC259,135$5.30M1.30%+117,619+83.1%Added
Goldman Sachs Group Inc262,272$5.37M0.00%+72,767+38.4%Added
Woodline Partners LP300,499$6.15M0.03%−800,158−72.7%Reduced
Logos Global Management LP340,000$6.96M0.69%−10,000−2.9%Reduced
Marshall Wace, LLP340,482$6.97M0.01%+7,149+2.1%Added
Charles Schwab Investment Management Inc363,202$7.43M0.00%+57,542+18.8%Added
Millennium Management LLC381,405$7.81M0.01%+62,956+19.8%Added
Northern Trust Corp394,452$8.07M0.00%+69,824+21.5%Added
Affinity Asset Advisors, LLC400,000$8.19M0.76%00.0%Unchanged
Franklin Resources Inc430,240$8.81M0.00%00.0%Unchanged
Candriam Luxembourg S.C.A.609,352$12.5M0.07%+192,702+46.3%Added
Rock Springs Capital Management LP686,107$14.0M0.82%−15,301−2.2%Reduced
5AM Venture Management, LLC772,477$15.8M5.79%00.0%Unchanged
First Turn Management, LLC783,411$16.0M2.41%+273,424+53.6%Added
Duquesne Family Office LLCSuperinvestorDuquesne Family Office947,405$19.4M0.49%+484,405+104.6%Added
State Street Corp965,137$19.8M0.00%+148,895+18.2%Added
Point72 Asset Management, L.P.1,040,410$21.3M0.05%−312,668−23.1%Reduced
Geode Capital Management, LLC1,085,013$22.2M0.00%+202,260+22.9%Added
Vestal Point Capital, LP1,160,000$23.7M1.08%+910,000+364.0%Added
Citadel Advisors LLC1,160,503$23.8M0.02%−309,921−21.1%Reduced
Capital Research Global Investors1,315,465$26.9M0.01%00.0%Unchanged
Blackstone Group Inc.1,320,592$27.0M0.12%00.0%Unchanged
Pictet Asset Management Holding SA1,398,087$28.6M0.03%+430,585+44.5%Added
Novo Holdings A/S1,426,260$29.2M1.88%+341,828+31.5%Added
Janus Henderson Group PLC1,793,583$36.7M0.02%+77,171+4.5%Added
Vanguard Group Inc2,553,014$52.3M0.00%+142,378+5.9%Added
Polar Capital Holdings Plc3,095,007$63.4M0.31%+44,713+1.5%Added
VR Adviser, LLC3,226,331$66.0M3.72%−800,000−19.9%Reduced
BlackRock, Inc.3,518,524$72.0M0.00%+551,390+18.6%Added
Fairmount Funds Management LLC3,711,444$76.0M6.84%00.0%Unchanged
Commodore Capital LP4,692,809$96.1M4.69%00.0%Unchanged
FMR LLC7,129,196$145.9M0.01%−430,705−5.7%Reduced
OrbiMed Advisors LLC7,959,538$162.9M3.91%00.0%Unchanged
Ra Capital Management, L.P.0$00.00%−848,986−100.0%Sold out
TCG Crossover Management, LLC0$00.00%−498,000−100.0%Sold out
Ally Bridge Group (NY) LLC0$00.00%−281,394−100.0%Sold out
Jane Street Group, LLC0$00.00%−56,981−100.0%Sold out
Weiss Asset Management LP0$00.00%−47,622−100.0%Sold out
Aster Capital Management (DIFC) Ltd0$00.00%−28,584−100.0%Sold out
Susquehanna Fundamental Investments, LLC0$00.00%−28,334−100.0%Sold out
Voloridge Investment Management, LLC0$00.00%−17,656−100.0%Sold out
Point72 (DIFC) Ltd0$00.00%−1,536−100.0%Sold out
IFP Advisors, Inc0$00.00%0Sold out
Allworth Financial LP0$00.00%−38−100.0%Sold out